There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Organogenesis Holdings (ORGO – Research Report) and Femasys (FEMY – Research Report) with bullish sentiments.
Organogenesis Holdings (ORGO)
BTIG analyst Ryan Zimmerman assigned a Buy rating to Organogenesis Holdings today and set a price target of $4.00. The company’s shares closed last Wednesday at $2.65.
According to TipRanks.com, Zimmerman is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Organogenesis Holdings with a $3.50 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Femasys (FEMY)
In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Femasys. The company’s shares closed last Wednesday at $1.11.
According to TipRanks.com, McCarthy is ranked 0 out of 5 stars with an average return of
Femasys has an analyst consensus of Strong Buy, with a price target consensus of $7.33, representing a 543.0% upside. In a report issued on September 26, JonesTrading also maintained a Buy rating on the stock with a $7.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ORGO:
- Organogenesis Holdings Inc. to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
- Organogenesis slides after reporting Q2 results, removing FY guidance
- Organogenesis price target lowered to $4 from $10 at BTIG
- Organogenesis Holdings Inc. Reports Second Quarter 2023 Financial Results; Withdraws Fiscal Year 2023 Guidance
- ORGO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
